2013
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clinical Ophthalmology 2013, Volume 7: 1867-1875. PMID: 24092965, PMCID: PMC3788817, DOI: 10.2147/opth.s32177.Peer-Reviewed Original ResearchCentral serous chorioretinopathySerous chorioretinopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsSafety of PDTTreatment of CSCRPhotodynamic therapyChronic recurrent formGrowth factor agentsPermanent visual lossPossible pathophysiologic mechanismsSerous retinal detachmentProspective interventional studyLong-term efficacyPigment epithelial detachmentPotential therapeutic optionEfficacy of PDTMajority of casesFactor agentsAnatomic improvementFoveal atrophyPigment epitheliopathyRetinal detachmentVisual lossFluorescein angiography
2012
ACUTE SYPHILITIC POSTERIOR PLACOID CHORIORETINITIS
Eandi CM, Neri P, Adelman RA, Yannuzzi LA, Cunningham ET. ACUTE SYPHILITIC POSTERIOR PLACOID CHORIORETINITIS. Retina 2012, 32: 1915-1941. PMID: 22863970, DOI: 10.1097/iae.0b013e31825f3851.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAnti-Bacterial AgentsCD4 Lymphocyte CountChorioretinitisColoring AgentsDrug Therapy, CombinationEye Infections, BacterialFemaleFluorescein AngiographyFluorescent Treponemal Antibody-Absorption TestGlucocorticoidsHIV SeropositivityHumansIndocyanine GreenInfusions, IntravenousMaleMiddle AgedPenicillin GRetrospective StudiesSyphilisTomography, Optical CoherenceVisual AcuityConceptsAcute syphilitic posterior placoid chorioretinitisPosterior placoid chorioretinitisCD4 cell countCells/μLAntibiotic therapyAngiographic featuresFluorescein angiographyPositive venereal disease research laboratoryCell countHuman immunodeficiency virus (HIV) coinfectionMedian CD4 cell countRapid plasma regain titerRecent CD4 cell countVenereal Disease Research LaboratoryFluorescent treponemal antibody absorptionEvidence of neurosyphilisMulticenter chart reviewOuter retinal lesionsImmunodeficiency virus coinfectionAppropriate antibiotic therapyPosterior segment examinationSeries of patientsHuman immunodeficiency virusPositive serologic testsRed-free photographsIntravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up
Zebardast N, Adelman RA. Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up. Seminars In Ophthalmology 2012, 27: 61-64. PMID: 22784267, DOI: 10.3109/08820538.2012.680644.Peer-Reviewed Original ResearchConceptsChoroidal neovascularizationOptical coherence tomographyPseudoxanthoma elasticumFluorescein angiographyNeovascular activityTreatment of CNVIntravitreal ranibizumab injectionsFive yearsMacular choroidal neovascularizationLong-term effectivenessOCT evidenceIntravitreal ranibizumabRanibizumab injectionsRanibizumab therapyAffected eyeIntraretinal fluidVisual acuityFluorescein leakageAngioid streaksScar formationInitial injectionCoherence tomographyRanibizumabInjectionNeovascularization
2009
Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization
Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization. Investigative Ophthalmology & Visual Science 2009, 50: 3890-3896. PMID: 19357351, DOI: 10.1167/iovs.08-2833.Peer-Reviewed Original ResearchConceptsVisudyne photodynamic therapyChoroidal neovascularizationCNV lesionsTargeted photodynamic therapyDay 7Rat modelSafety of PDTPhotodynamic therapyOcular side effectsBrown Norway ratsFrequency of leakageFluorescein angiographyEfficacious doseHistopathologic evaluationLaser photocoagulationSide effectsFactor VIIDay 14LesionsNormal vasculatureRatsEndothelial cellsTherapyDoseNeovascularization
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator